Diagnostic value of miR-128-3p， SIRT1， and AMPK in patients with type 2 diabetes mellitus comorbid with nonalcoholic fatty liver disease

Juyi LI; Yingqun NI; Yuanyuan ZHANG; Huaizhen LIU

doi:10.12449/JCH250310

Volume 41 Issue 3

Mar. 2025

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2025 > 41(3): 453-460

PDF( 1188 KB)

Diagnostic value of miR-128-3p， SIRT1， and AMPK in patients with type 2 diabetes mellitus comorbid with nonalcoholic fatty liver disease

DOI: 10.12449/JCH250310

1.
Department of Endocrinology Center for Geriatrics, The First Affiliated Hospital of Anhui University of Chinese Medicine，Hefei 230031，China
2.
Department of Endocrinology The First Affiliated Hospital of Anhui University of Chinese Medicine，Hefei 230031，China

Research funding:

National Natural Science Foundation of China (82274468);

Anhui Provincial University Scientific Research Project-Major Project (2023AH040103);

Anhui University of Traditional Chinese Medicine Research Project (2021yfylc49)

More Information

Corresponding author: LIU Huaizhen， liuhuaizhen0723@163.com （ORCID： 0009-0002-6533-969X）
Received Date: 2024-07-23
Accepted Date: 2024-09-19
Published Date: 2025-03-25

Abstract

Abstract

Objective To investigate the expression levels of miR-128-3p， SIRT1， and AMPK in the peripheral blood of patients with type 2 diabetes mellitus （T2DM） comorbid with nonalcoholic fatty liver disease （NAFLD）， as well as the role of miR-128-3p in predicting NAFLD in T2DM patients. Methods A total of 80 patients with T2DM who were hospitalized in The First Affiliated Hospital of Anhui University of Chinese Medicine from September 2022 to August 2023 were enrolled and divided into T2DM group with 40 patients and NAFLD group with 40 patients， and according to the NAFLD fibrosis score （NFS）， the patients were further divided into progressive liver fibrosis group with 16 patients and non-progressive liver fibrosis group with 64 patients. General data and biochemical parameters were collected； quantitative real-time PCR was used to measure the mRNA expression levels of miR-128-3p， SIRT1， and AMPK in peripheral blood， and Western blot was used to measure the protein expression levels of SIRT1 and AMPK. The independent-samples t test was used for comparison of normally distributed data between two groups， and the Mann-Whitney U test was used for comparison of data with skewed distribution between two groups； the chi-square test was used for comparison of categorical data between two groups. The logistic regression analysis was used to identify the influencing factors for the presence of NAFLD and progressive liver fibrosis， and the receiver operating characteristic （ROC） curve analysis was used to determine the optimal cut-off value of miR-128-3p for predicting NAFLD. Results There were significant differences between the NAFLD group and the non-NAFLD group in body mass index， fasting plasma glucose， glycated hemoglobin， fasting insulin， fasting C-peptide， alanine aminotransferase （ALT）， aspartate aminotransferase， gamma-glutamyl transpeptidase， alkaline phosphatase， fibronectin， triglycerides， high-density lipoprotein cholesterol， total triiodothyronine （TT3）， Homeostasis Model Assessment of Insulin Resistance （HOMA-IR）， and NFS （all P<0.05）. Compared with the non-NAFLD group， the NAFLD group had a significantly higher mRNA expression level of miR-128-3p in peripheral blood （t=-8.765， P<0.001） and significant reductions in the mRNA and proteins expression levels of SIRT1 and AMPK （P<0.001）. There were significant differences between the progressive liver fibrosis group and the non-progressive liver fibrosis group in age， ALT， free triiodothyronine， TT3， superoxide dismutase， and miR-128-3p （all P<0.05）. The logistic regression analysis showed that miR-128-3p was an independent risk factor for the development of NAFLD （odds ratio ［OR］=8.221， 95% confidence interval ［CI］： 2.735 — 24.714， P<0.001） and progressive liver fibrosis （OR=1.493， 95%CI： 1.117‍ ‍—‍ ‍1.997， P=0.007）. The ROC curve analysis showed that miR-128-3p had an area under the ROC curve of 0.890 （95%CI： 0.829 — 0.950）， with an optimal cut-off value of 13.165， a sensitivity of 89.3%， and a specificity of 72.7%. Conclusion There is an increase in the expression of miR-128-3p in peripheral blood of T2DM patients with NAFLD， while there are reductions in the expression levels of SIRT1 and AMPK， suggesting that miR-128-3p has a certain diagnostic value in identifying NAFLD and liver fibrosis in such population.
- Diabetes Mellitus， Type 2,
- Non-alcoholic Fatty Liver Disease,
- MicroRNAs,
- Sirtuin 1,
- AMP-Activated Protein Kinases

FullText(HTML)

References(33)

References

[1]	LI L, LIU DW, YAN HY, et al. Obesity is an independent risk factor for non-alcoholic fatty liver disease: Evidence from a meta-analysis of 21 cohort studies[J]. Obes Rev, 2016, 17( 6): 510- 519. DOI: 10.1111/obr.12407.
[2]	WORETA TA, van NATTA ML, LAZO M, et al. Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis(NASH) in a North American cohort and comparison to other non-invasive algorithms[J]. PLoS One, 2022, 17( 4): e0266859. DOI: 10.1371/journal.pone.0266859.
[3]	CHO EEL, ANG CZ, QUEK J, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: An updated systematic review and meta-analysis[J]. Gut, 2023, 72( 11): 2138- 2148. DOI: 10.1136/gutjnl-2023-330110.
[4]	SANYAL AJ, van NATTA ML, CLARK J, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease[J]. N Engl J Med, 2021, 385( 17): 1559- 1569. DOI: 10.1056/NEJMoa2029349.
[5]	ALON L, CORICA B, RAPARELLI V, et al. Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. Eur J Prev Cardiol, 2022, 29( 6): 938- 946. DOI: 10.1093/eurjpc/zwab212.
[6]	BISACCIA G, RICCI F, KHANJI MY, et al. Cardiovascular morbidity and mortality related to non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. Curr Probl Cardiol, 2023, 48( 6): 101643. DOI: 10.1016/j.cpcardiol.2023.101643.
[7]	WANG L, SINNOTT-ARMSTRONG N, WAGSCHAL A, et al. A MicroRNA linking human positive selection and metabolic disorders[J]. Cell, 2020, 183( 3): 684- 701. e 14. DOI: 10.1016/j.cell.2020.09.017.
[8]	ZHAO XR, JIN Y, LI L, et al. MicroRNA-128-3p aggravates doxorubicin-induced liver injury by promoting oxidative stress via targeting Sirtuin-1[J]. Pharmacol Res, 2019, 146: 104276. DOI: 10.1016/j.phrs.2019.104276.
[9]	SHI RF, JIN YP, HU WW, et al. Exosomes derived from mmu_circ_0000250-modified adipose-derived mesenchymal stem cells promote wound healing in diabetic mice by inducing miR-128-3p/SIRT1-mediated autophagy[J]. Am J Physiol Cell Physiol, 2020, 318( 5): C848- C856. DOI: 10.1152/ajpcell.00041.2020.
[10]	HAN JN, HAO WJ, MA YP, et al. MiR-128-3p promotes the progression of deep venous thrombosis through binding SIRT1[J]. Phlebology, 2023, 38( 8): 540- 549. DOI: 10.1177/02683555231190268.
[11]	Diabetes Society of Chinese Medical Association. Guideline for the prevention and treatment of type 2 diabetes mellitus in China(2020 edition)[J]. Chin J Diabetes, 2021, 13( 4): 315- 409. DOI: 10.3760/cma.j.cn115791-20210307-00135. 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13( 4): 315- 409. DOI: 10.3760/cma.j.cn115791-20210307-00135.
[12]	National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association, Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007. 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
[13]	WANG XS, JIANG LJ, SHAO XN. Association analysis of insulin resistance and osteoporosis risk in Chinese patients with T2DM[J]. Ther Clin Risk Manag, 2021, 17: 909- 916. DOI: 10.2147/TCRM.S328510.
[14]	ANGULO P, HUI JM, MARCHESINI G, et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD[J]. Hepatology, 2007, 45( 4): 846- 854. DOI: 10.1002/hep.21496.
[15]	TARGHER G, COREY KE, BYRNE CD, et al. The complex link between NAFLD and type 2 diabetes mellitus—Mechanisms and treatments[J]. Nat Rev Gastroenterol Hepatol, 2021, 18( 9): 599- 612. DOI: 10.1038/s41575-021-00448-y.
[16]	STEFAN N, CUSI K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes[J]. Lancet Diabetes Endocrinol, 2022, 10( 4): 284- 296. DOI: 10.1016/S2213-8587(22)00003-1.
[17]	SONG SJ, LAI JCT, WONG GLH, et al. Can we use old NAFLD data under the new MASLD definition?[J]. J Hepatol, 2024, 80( 2): e54- e56. DOI: 10.1016/j.jhep.2023.07.021.
[18]	MANTOVANI A, CSERMELY A, TAVERNA A, et al. Association between metabolic dysfunction-associated fatty liver disease and supraventricular and ventricular tachyarrhythmias in patients with type 2 diabetes[J]. Diabetes Metab, 2023, 49( 2): 101416. DOI: 10.1016/j.diabet.2022.101416.
[19]	NI XT, TONG C, HALENGBIEKE A, et al. Association between nonalcoholic fatty liver disease and type 2 diabetes: A bidirectional two-sample Mendelian randomization study[J]. Diabetes Res Clin Pract, 2023, 206: 110993. DOI: 10.1016/j.diabres.2023.110993.
[20]	ISMAIL MH, ARGAN R AL, ELAMIN Y, et al. Automated fibrosis-4 index: Simplifying non-alcoholic fatty liver disease for diabetologists[J]. Medicina(Kaunas), 2024, 60( 8): 1278. DOI: 10.3390/medicina60081278.
[21]	O’CONNELL RM, RAO DS, BALTIMORE D. MicroRNA regulation of inflammatory responses[J]. Annu Rev Immunol, 2012, 30: 295- 312. DOI: 10.1146/annurev-immunol-020711-075013.
[22]	UDDIN A, CHAKRABORTY S. Role of miRNAs in lung cancer[J]. J Cell Physiol, 2018. DOI: 10.1002/jcp.26607.[ Online ahead of print]
[23]	YANG JN, JIANG TL, ZHU FB, et al. Research progress in effect of miRNA on podocyte injury in diabetic nephropathy and its mechanism[J]. J Jilin Univ(Med Edit), 2023, 49( 6): 1677- 1682. DOI: 10.13481/j.1671-587X.20230637. 杨佳楠, 姜同连, 朱福彬, 等. miRNA在糖尿病肾病足细胞损伤中作用及其机制的研究进展[J]. 吉林大学学报(医学版), 2023, 49( 6): 1677- 1682. DOI: 10.13481/j.1671-587X.20230637.
[24]	WEI HF, NI ZQ, WEI YH, et al. Effects of miR-126 over-expression and ADAM9 gene silencing on biological behavior of gastric cancer SGC-7901 cells and their mechanisms[J]. J Jilin Univ(Med Edit), 2024, 50( 2): 310- 319. DOI: 10.13481/j.1671-587X.20240203. 魏海峰, 倪志强, 魏雁虹, 等. MiR-126过表达和ADAM9基因沉默对胃癌SGC-7901细胞生物学行为的影响及其机制[J]. 吉林大学学报(医学版), 2024, 50( 2): 310- 319. DOI: 10.13481/j.1671-587X.20240203.
[25]	SUN T, WANG C, HUO L, et al. Serum cortistatin level in type 2 diabetes mellitus and its relationship with nonalcoholic fatty liver disease[J]. Int J Gen Med, 2023, 16: 631- 639. DOI: 10.2147/IJGM.S396315.
[26]	HIRANO T, SATOH N, ITO Y. Specific increase in small dense low-density lipoprotein-cholesterol levels beyond triglycerides in patients with diabetes: Implications for cardiovascular risk of MAFLD[J]. J Atheroscler Thromb, 2024, 31( 1): 36- 47. DOI: 10.5551/jat.64271.
[27]	BI TB. Relationship between thyroid hormone levels and metabolic dysfunction associated steatotic liver disease in patients with type 2 diabetes: A clinical study[J]. Medicine(Baltimore), 2024, 103( 26): e38643. DOI: 10.1097/MD.0000000000038643.
[28]	ZHANG XD, CHEN YM, YE HY, et al. Correlation between thyroid function, sensitivity to thyroid hormones and metabolic dysfunction-associated fatty liver disease in euthyroid subjects with newly diagnosed type 2 diabetes[J]. Endocrine, 2023, 80( 2): 366- 379. DOI: 10.1007/s12020-022-03279-2.
[29]	HEIANZA Y, XUE QC, ROOD J, et al. Circulating thrifty microRNA is related to insulin sensitivity, adiposity, and energy metabolism in adults with overweight and obesity: The POUNDS lost trial[J]. Am J Clin Nutr, 2023, 117( 1): 121- 129. DOI: 10.1016/j.ajcnut.2022.10.001.
[30]	CHANG E. Vitamin D mitigates hepatic fat accumulation and inflammation and increases SIRT1/AMPK expression in AML-12 hepatocytes[J]. Molecules, 2024, 29( 6): 1401. DOI: 10.3390/molecules29061401.
[31]	XIAO Q, ZHANG SJ, YANG C, et al. Ginsenoside Rg1 ameliorates palmitic acid-induced hepatic steatosis and inflammation in HepG2 cells via the AMPK/NF-κB pathway[J]. Int J Endocrinol, 2019, 2019: 7514802. DOI: 10.1155/2019/7514802.
[32]	WU LZ, ZHANG GR, GUO CB, et al. MiR-128-3p mediates TNF-α-induced inflammatory responses by regulating Sirt1 expression in bone marrow mesenchymal stem cells[J]. Biochem Biophys Res Commun, 2020, 521( 1): 98- 105. DOI: 10.1016/j.bbrc.2019.10.083.
[33]	SAMY AM, KANDEIL MA, SABRY D, et al. Exosomal miR-122, miR-128, miR-200, miR-298, and miR-342 as novel diagnostic biomarkers in NAFL/NASH: Impact of LPS/TLR-4/FoxO3 pathway[J]. Arch Pharm(Weinheim), 2024, 357( 4): e2300631. DOI: 10.1002/ardp.202300631.

Relative Articles

[1]	Yongning XU, Xuehuan HUANG, Zhipan TANG, Ruohan LI, Wen QIN. Establishment and in vivo imaging observation of a nude mouse model of type 2 diabetes mellitus and pancreatic cancer[J]. Journal of Clinical Hepatology, 2024, 40(6): 1231-1239. doi: 10.12449/JCH240625
[2]	Haoxin DUAN, Yuyong JIANG, Tingyu WU, Feixiang XIONG, Yandan JIANG, Qin ZHANG, Saisai ZHAO, Hao YU. The genetic association between nonalcoholic fatty liver disease and type 2 diabetes mellitus in different body mass index categories： A bidirectional Mendelian randomization study[J]. Journal of Clinical Hepatology, 2024, 40(10): 1992-1999. doi: 10.12449/JCH241011
[3]	Shunxiao ZHANG, Sheng ZHANG, Yan ZHANG, Yuanyuan LI, Yue CHEN, Mingyu SUN. Influencing factors for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus[J]. Journal of Clinical Hepatology, 2023, 39(5): 1081-1088. doi: 10.3969/j.issn.1001-5256.2023.05.013
[4]	Fangfang QIAN, Meiqing DAI, Li ZHAO, Xia DENG, Ling YANG, Jue JIA, Jifang WANG, Dong WANG, Guoyue YUAN. Association between serum alkaline phosphatase and type 2 diabetes mellitus with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(1): 83-88. doi: 10.3969/j.issn.1001-5256.2023.01.013
[5]	Dongxu WANG, Nan NAN, Hao BING, Lianjie LIN. Value of triglyceride-glucose index and body mass index in predicting nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus[J]. Journal of Clinical Hepatology, 2022, 38(5): 1064-1068. doi: 10.3969/j.issn.1001-5256.2022.05.017
[6]	Deyun WANG, Ruirui JIN, Zhen ZHAO, Hui LI. Brain abscess secondary to liver abscess in type 2 diabetes mellitus: A case report[J]. Journal of Clinical Hepatology, 2022, 38(6): 1375-1376. doi: 10.3969/j.issn.1001-5256.2022.06.031
[7]	Heng ZHU, Weizong KONG, Guiqun HUANG, Yu BAI, Yingchun WANG. Influence of histone deacetylase 1 on insulin resistance in a cell model of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(9): 2010-2015. doi: 10.3969/j.issn.1001-5256.2022.09.013
[8]	Jiao LIU, Caiqin REN, Yali FENG, Jirui HE. Association between liver fibrosis and C-peptide in patients with type 2 diabetes and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(5): 1132-1136. doi: 10.3969/j.issn.1001-5256.2021.05.030
[9]	Shengnan DU, Jingjing GAO, Tao WANG, Yuanye JIANG, Qin CAO. Value of circular RNA in the diagnosis and treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(11): 2684-2688. doi: 10.3969/j.issn.1001-5256.2021.11.043
[10]	Renshu MA, Tong WU, Ge YU, Ying CONG, Guijie XIN. A case of type 2 diabetes with glycogenic hepatopathy[J]. Journal of Clinical Hepatology, 2021, 37(9): 2183-2184. doi: 10.3969/j.issn.1001-5256.2021.09.035
[11]	Zhihua ZUO, Chuyi ZENG, Yao JIANG, Hualin TAO, Yongcan GUO. Regulatory role of long non-coding RNAs in the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(7): 1704-1707. doi: 10.3969/j.issn.1001-5256.2021.07.048
[12]	Liu Ting, Wang ChenTing, Liu MeiXiao, Liu JianFeng, Zheng ShaoXiong. Association between liver fibrosis and serum uric acid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(6): 1320-1324. doi: 10.3969/j.issn.1001-5256.2020.06.026
[13]	Yan HongMei. Can type 2 diabetes mellitus be reversed by improving nonalcoholic fatty liver disease?[J]. Journal of Clinical Hepatology, 2020, 36(6): 1213-1216. doi: 10.3969/j.issn.1001-5256.2020.06.004
[14]	Xie HaiPing, Lin Fan, Chen Yan, Zheng Ming. Advances in liraglutide in the treatment of type 2 diabetes with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(9): 2111-2114. doi: 10.3969/j.issn.1001-5256.2020.09.046
[15]	Li XiaoJing, Sun YuanLong, Zhang BinBin, Mei ZuBing, Feng Qin, Hu YiYang. Efficacy and safety of sodium-glucose co-transporter 2 inhibitors in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease: A meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(10): 2241-2247. doi: 10.3969/j.issn.1001-5256.2020.10.016
[16]	ZHANG SuYan, XIA EnRui, ZHOU QingLi, ZHANG ShunZhen. Effect of Quzhi Ruangan decoction on the mRNA and protein expression of organic anion transporting polypeptide 2B1 in the small intestine of rats with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2484-2488. doi: 10.3969/j.issn.1001-5256.2020.11.017
[17]	Wang Fan, Sun Wu, Ma YuLin, Jiang HongJun. Association between microRNA-155/SH2-containing inositol phosphatase-1 and cardiovascular events in patients with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(6): 1325-1329. doi: 10.3969/j.issn.1001-5256.2020.06.027
[18]	Xue MiaoMiao, Li XuePing, Li Ya, Yan NaNa, Xu GangZhu, Song Mei. Research advances in sodium-glucose co-transporter 2 inhibitor in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(12): 2812-2816. doi: 10.3969/j.issn.1001-5256.2019.12.037
[19]	Yang Shuai, He SongQing. Role of silent information regulator 1 in development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(3): 649-652. doi: 10.3969/j.issn.1001-5256.2018.03.047
[20]	Mai JingYin, Chen TianYang, Cheng Yang. Changes in microRNA expression profile in the liver of mice with nonalcoholic fatty liver disease induced by high-fat diet[J]. Journal of Clinical Hepatology, 2017, 33(12): 2372-2375. doi: 10.3969/j.issn.1001-5256.2017.12.023

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(6)

Get Citation

PDF

XML

Article Metrics

Article views (52) PDF downloads(9)

Diagnostic value of miR-128-3p， SIRT1， and AMPK in patients with type 2 diabetes mellitus comorbid with nonalcoholic fatty liver disease

DOI: 10.12449/JCH250310

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Diagnostic value of miR-128-3p， SIRT1， and AMPK in patients with type 2 diabetes mellitus comorbid with nonalcoholic fatty liver disease

DOI: 10.12449/JCH250310

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content